Chronic imipramine treatment reduces inhibitory properties of group II mGlu receptors without affecting their density or affinity

Pharmacological Reports

Volumn 59, Issue 5, 2007, Pages 525-530

  Pałucha, Agnieszka ^a   Brański, Piotr ^a   Kłak, Kinga ^a   Sowa, Magdalena ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

cAMP; Group II mGlu receptors; Imipramine

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; ANTIDEPRESSANT AGENT; CYCLIC AMP; FORSKOLIN; GLUTAMIC ACID; IMIPRAMINE; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; CONTROLLED STUDY; DEPRESSION; DRUG MECHANISM; FRONTAL CORTEX; HIPPOCAMPUS; INHIBITION KINETICS; MALE; NONHUMAN; PATHOPHYSIOLOGY; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY;

EID: 38049126174     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000, 47, 351-354.
2. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T et al.: MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology, 2004, 46, 457-467.
3. Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK: Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom Med, 1999, 61, 599-617.
4. Chen J, Rasenick MM: Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J Pharmacol Exp Ther, 1995, 275, 509-517.
5. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol, 1997, 37, 205-237.
6. Garcia-Sevilla JA, Escriba PV, Ozaita A, La Harpe R, Walzer C, Eytan A, Guimon J: Up-regulation of immunolabeled alpha2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J Neurochem, 1999, 72, 282-291.
7. Legutko B, Szewczyk B, Pomiemy-Chamioło L, Nowak G, Pilc A: Effect of MPEP treatment of brain-derived neurotrophic; factor gene expression. Pharmacol Rep, 2006, 58, 427-430.
8. Matrisciano F, Scaccianoce S, Del Bianco P, Panaccione I, Canudas AM, Battaglia G: Metabotropic glutamate receptors and neuroadaptation to antidepressants: imipramine-induced down-regulation of beta-adrenergic receptors in mice treated with metabotropic glutamate 2/3 receptor ligands. J Neurochem, 2005, 93, 1345-1352.
9. Matrisciano F, Storto M, Ngomba RT, Cappuccio, I, Caricasole A, Scaccianoce S, Riozzi B et al.: Imipramine treatment up-regulates the expression and function of mGlu2/3 metabotropic glutamate receptors in the rat hippocampus. Neuropharmacology, 2002, 42, 1008-1015.
10. Millan MJ: Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther, 2006, 110, 135-370.
11. Newton SS, Thome J, Wallace TL, Shirahama Y, Schlesinger L, Sakai N, Chen J, et al.: Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci, 2002, 22, 10883-10890.
12. Palucha A, Brański P, Kroczka B, Pilc A: Possible involvement of mGluR1 together with group II and III mGluRs in ibotenate-stimulated cAMP formation in the rat brain cortical slices. Pol J Pharmacol, 2000, 52, 353-358.
13. Pałucha A, Pilc A: Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther, 2007, doi: 10.1016/j.pharmthera.2007.04.007.
14. Pilc A, Brański P, Pałucha A, Tokarski K, Bijak M: Antidepressant treatment influences group I of glutamate metabotropic receptors in slices from hippocampal CA1 region. Eur J Pharmacol, 1998, 349, 83-87.
15. Popoli M, Brunello N, Perez J, Racagni G: Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. J Neurochem, 2000, 74, 21-33.
16. Schoepp DD: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. J Pharmacol Exp Ther, 2001, 299, 12-20.
17. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40.
18. Śmiałowska. M, Szewczyk B, Brański P, Wierońska JM, Pałucha A, Bajkowska M, Pilc A: Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42, 1016-1023.
19. Tamaru Y, Nomura S, Mizuno N, Shigemoto R: Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience, 2001, 106, 481-503.
20. Wright RA, Arnold MB, Wheeler WJ, Ornstein PL, Schoepp DD: [H-3]LY341495 binding to group II metabotropic glutamate receptors in rat brain. J Pharmacol Exp Ther, 2001, 298, 453-460.
21. Yoshimizu T, Shimazaki T, Ito A, Chaki S: An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology, 2006, 186, 587-593.
22. Zahorodna A, Bijak, M: An antidepressant-induced decrease in the responsiveness of hippocampal neurons to group I metabotropic glutamate receptor activation. Eur J Pharmacol, 1999, 386, 173-179.
23. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Manji HK, Charney DS: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864.